Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 6: 788 - 794

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.06.015

Review

Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response

  • Yong ZHANG ,
  • Weihong LI ,
  • Zhipeng CHENG ,
  • bin WANG ,
  • Siheng WANG ,
  • Yubin WANG
Expand
  • 1.The Fifth Clinical Medical College of Shanxi Medical University, Taiyuan 030012, China
    2.Department of Urology, Shanxi Provincial People′s Hospital, Shanxi Medical University, Taiyuan 030012, China
WANG Yubin, E-mail: wangyb1980@163.com.

Received date: 2024-01-09

  Accepted date: 2024-04-12

  Online published: 2024-06-28

Supported by

Natural Science Foundation of Shanxi Province(202103021224375);Fund Program for the Scientific Activities of Selected Returned Overseas Professionals in Shanxi Province(2022047);Research Project Supported by Shanxi Scholarship Council of China(2022-204)

Fold

Abstract

Receptor-interacting protein kinase 1 (RIPK1) is a multi-domain serine/threonine protein kinase that causes downstream signal transduction and biological effects by phosphorylating specific proteins. In recent years, with the in-depth study of RIPK1, scholars have found that it is of great significance in autoimmune diseases, neurodegenerative diseases, and a variety of solid tumors and hematological tumors. On the one hand, RIPK1 promotes cell survival and inflammatory responses by activating specific pathways such as nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK). On the other hand, RIPK1 promotes apoptosis by interacting with cysteinyl aspartate specific proteinase-8 (caspase-8), or promotes necroptosis by interacting with RIPK3 and mixed lineage kinase domain-like protein (MLKL). As an upstream signal, RIPK1 has different expression levels in patients with different tumors. Its scaffold function and kinase activity can regulate cancer progression, initiate adaptive immunity, inhibit tumor progression, and generate an immunosuppressive tumor microenvironment to promote tumor development. Its dual role has been demonstrated in regulating the occurrence and development of tumors and the body's immune response, and can be used as a new therapeutic target to control cancer progression. This paper starts with the structure of RIPK1 to further explore its function in regulating cancer progression and immune response, and to provide new ideas for the development of cancer-targeted drugs.

Key words： receptor-interacting protein kinase 1 (RIPK1); necrotizing apoptosis; necrotic complex; cancer; immune response; targeted therapy

Cite this article

Yong ZHANG , Weihong LI , Zhipeng CHENG , bin WANG , Siheng WANG , Yubin WANG . Research status of receptor-interacting protein kinase 1 in regulating cancer progression and immune response[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(6) : 788 -794 . DOI: 10.3969/j.issn.1674-8115.2024.06.015

References

1 DEGTEREV A, HUANG Z H, BOYCE M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury[J]. Nat Chem Biol, 2005, 1(2): 112-119.
2 SHAN B, PAN H L, NAJAFOV A, et al. Necroptosis in development and diseases[J]. Genes Dev, 2018, 32(5/6): 327-340.
3 DOVEY C M, DIEP J, CLARKE B P, et al. MLKL requires the inositol phosphate code to execute necroptosis[J]. Mol Cell, 2018, 70(5): 936-948.e7.
4 SEIFERT L, WERBA G, TIWARI S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression[J]. Nature, 2016, 532(7598): 245-249.
5 KONDYLIS V, PASPARAKIS M. RIP kinases in liver cell death, inflammation and cancer[J]. Trends Mol Med, 2019, 25(1): 47-63.
6 YAN J, WAN P X, CHOKSI S, et al. Necroptosis and tumor progression[J]. Trends Cancer, 2022, 8(1): 21-27.
7 MIFFLIN L, OFENGEIM D, YUAN J Y. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target[J]. Nat Rev Drug Discov, 2020, 19(8): 553-571.
8 LI W J, YUAN J Y. Targeting RIPK1 kinase for modulating inflammation in human diseases[J]. Front Immunol, 2023, 14: 1159743.
9 HE S D, WANG X D. RIP kinases as modulators of inflammation and immunity[J]. Nat Immunol, 2018, 19(9): 912-922.
10 RIEBELING T, KUNZENDORF U, KRAUTWALD S. The role of RHIM in necroptosis[J]. Biochem Soc Trans, 2022, 50(4): 1197-1205.
11 WU G W, LI D K, LIANG W, et al. PP6 negatively modulates LUBAC-mediated M1-ubiquitination of RIPK1 and c-FLIPL to promote TNFα-mediated cell death[J]. Cell Death Dis, 2022, 13(9): 773.
12 DRABER P, KUPKA S, REICHERT M, et al. LUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes[J]. Cell Rep, 2015, 13(10): 2258-2272.
13 YUAN J Y, AMIN P, OFENGEIM D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases[J]. Nat Rev Neurosci, 2019, 20(1): 19-33.
14 DONDELINGER Y, DARDING M, BERTRAND M J, et al. Poly-ubiquitination in TNFR1-mediated necroptosis[J]. Cell Mol Life Sci, 2016, 73(11/12): 2165-2176.
15 XU D C, JIN T J, ZHU H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging[J]. Cell, 2018, 174(6): 1477-1491.e19.
16 WERTZ I, DIXIT V. A20: a bipartite ubiquitin editing enzyme with immunoregulatory potential[J]. Adv Exp Med Biol, 2014, 809: 1-12.
17 GONG Y T, FAN Z Y, LUO G P, et al. The role of necroptosis in cancer biology and therapy[J]. Mol Cancer, 2019, 18(1): 100.
18 LI X M, LI F, ZHANG X X, et al. Caspase-8 auto-cleavage regulates programmed cell death and collaborates with RIPK3/MLKL to prevent lymphopenia[J]. Cell Death Differ, 2022, 29(8): 1500-1512.
19 SALEH D, NAJJAR M, ZELIC M, et al. Kinase activities of RIPK1 and RIPK3 can direct IFN-β synthesis induced by lipopolysaccharide[J]. J Immunol, 2017, 198(11): 4435-4447.
20 LINKERMANN A, GREEN D R. Necroptosis[J]. N Engl J Med, 2014, 370(5): 455-465.
21 LIU T J, ZONG H F, CHEN X Y, et al. Toll-like receptor 4-mediated necroptosis in the development of necrotizing enterocolitis[J]. Pediatr Res, 2022, 91(1): 73-82.
22 BRISSE M, LY H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5[J]. Front Immunol, 2019, 10: 1586.
23 ZHANG T, YIN C R, BOYD D F, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis[J]. Cell, 2020, 180(6): 1115-1129.e13.
24 LIN J, KUMARI S, KIM C, et al. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation[J]. Nature, 2016, 540(7631): 124-128.
25 DEGTEREV A, OFENGEIM D, YUAN J Y. Targeting RIPK1 for the treatment of human diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(20): 9714-9722.
26 DILLON C P, WEINLICH R, RODRIGUEZ D A, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3[J]. Cell, 2014, 157(5): 1189-1202.
27 IMANISHI T, UNNO M, YONEDA N, et al. RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8[J]. Sci Adv, 2023, 9(4): eadd6097.
28 YATIM N, JUSFORGUES-SAKLANI H, OROZCO S, et al. RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8? T cells[J]. Science, 2015, 350(6258): 328-334.
29 MANDAL R, BARRóN J C, KOSTOVA I, et al. Caspase-8: the double-edged sword[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(2): 188357.
30 WU B Y, LI J Y, WANG H, et al. RIPK1 is aberrantly expressed in multiple B-cell cancers and implicated in the underlying pathogenesis[J]. Discov Oncol, 2023, 14(1): 131.
31 CAO L Y, MU W. Necrostatin-1 and necroptosis inhibition: pathophysiology and therapeutic implications[J]. Pharmacol Res, 2021, 163: 105297.
32 KATSUYA K, OIKAWA D, IIO K, et al. Small-molecule inhibitors of linear ubiquitin chain assembly complex (LUBAC), HOIPINs, suppress NF- κB signaling[J]. Biochem Biophys Res Commun, 2019, 509(3): 700-706.
33 WANG Y K, MA N, XU S, et al. PPDPF suppresses the development of hepatocellular carcinoma through TRIM21-mediated ubiquitination of RIPK1[J]. Cell Rep, 2023, 42(4): 112340.
34 JUNG S Y, PARK J I, JEONG J H, et al. Receptor interacting protein 1 knockdown induces cell death in liver cancer by suppressing STAT3/ATR activation in a p53-dependent manner[J]. Am J Cancer Res, 2022, 12(6): 2594-2611.
35 YU Y Q, THONN V, PATANKAR J V, et al. SMYD2 targets RIPK1 and restricts TNF-induced apoptosis and necroptosis to support colon tumor growth[J]. Cell Death Dis, 2022, 13(1): 52.
36 LIN P H, LIN C L, HE R F, et al. TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer[J]. Cell Death Dis, 2023, 14(1): 6.
37 BAI W Q, CUI F J, WANG Z H, et al. Receptor-interacting protein kinase 1 (RIPK1) regulates cervical cancer cells via NF-κB-TNF-α pathway: an in vitro study[J]. Transl Oncol, 2023, 36: 101748.
38 KHAMSEH M E, SHEIKHI A, SHAHSAVARI Z, et al. Evaluation of the expression of necroptosis pathway mediators and its association with tumor characteristics in functional and non-functional pituitary adenomas[J]. BMC Endocr Disord, 2022, 22(1): 1.
39 PATEL S, WEBSTER J D, VARFOLOMEEV E, et al. RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases[J]. Cell Death Differ, 2020, 27(1): 161-175.
40 H?NGGI K, VASILIKOS L, VALLS A F, et al. RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function[J]. Cell Death Dis, 2017, 8(2): e2588.
41 LI Y S, XIONG Y, ZHANG G, et al. Identification of 5-(2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as a new class of receptor-interacting protein kinase 1 (RIPK1) inhibitors, which showed potent activity in a tumor metastasis model[J]. J Med Chem, 2018, 61(24): 11398-11414.
42 ZHU G W, DU Q, CHEN X, et al. Receptor-interacting serine/threonine-protein kinase 1 promotes the progress and lymph metastasis of gallbladder cancer[J]. Oncol Rep, 2019, 42(6): 2435-2449.
43 MCCORMICK K D, GHOSH A, TRIVEDI S, et al. Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma[J]. Carcinogenesis, 2016, 37(5): 522-529.
44 CUCHET-LOUREN?O D, ELETTO D, WU C X, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation[J]. Science, 2018, 361(6404): 810-813.
45 LI Y, FüHRER M, BAHRAMI E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases[J]. Proc Natl Acad Sci U S A, 2019, 116(3): 970-975.
46 LALAOUI N, BOYDEN S E, ODA H, et al. Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease[J]. Nature, 2020, 577(7788): 103-108.
47 TAO P F, SUN J Q, WU Z M, et al. A dominant autoinflammatory disease caused by non-cleavable variants of RIPK1[J]. Nature, 2020, 577(7788): 109-114.
48 AAES T L, KACZMAREK A, DELVAEYE T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity[J]. Cell Rep, 2016, 15(2): 274-287.
49 CUCOLO L, CHEN Q Z, QIU J Y, et al. The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade[J]. Immunity, 2022, 55(4): 671-685.e10.
Options
Outlines

/

〈 〉